Please assess the completion status of the following clinical trial:

Trial Title: Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic colorectal cancer~  * Biopsy proven adenocarcinoma compatible with colorectal origin (primary tumor or metastasis)~ * If only biopsy from metastasis can be obtained, the patient must have a previously resected or image proven tumor of the colon or rectum (scanning or endoscopy)~ * Non-resectable metastatic spread~* Previously exposed to or intolerance or contraindications to standard systemic therapy, defined as~  * oxaliplatin~ * irinotecan~ * 5-fluorouracil (or similar such as capecitabine, S1)~ * VEGF inhibitor bevacizumab~ * EGFR inhibitor panitumumab or cetuximab (if RAS/RAF wt)~* Progressive disease defined as progression according to RECIST 1.1~* ECOG performance status 0-2~* Age at least 18 years~* Adequate bone marrow, liver and renal function allowing systemic chemotherapy~  * Absolute neutrophil count ≥1.5x10\^9/l and thrombocytes ≥ 100x10\^9/l.~ * Bilirubin ≤ 1.5 x upper normal value and alanine aminotransferase ≤ 3 x upper normal value~ * Calculated or measured renal glomerular filtration rate at least 30 mL/min~* Anticonception for fertile women and for male patients with a fertile partner. Intrauterine device, vasectomy of a female subject's male partner or hormonal contraceptive are acceptable~* Written and orally informed consent~Exclusion Criteria:~* Incapacity, frailty, disability, or comorbidity to a degree that according to the investigator is not compatible with participation in the protocol~* Other active malignant disease requiring therapy~* Other systemic anti-cancer therapy (palliative radiotherapy is allowed).~* Pregnant (positive pregnancy test) or breast feeding women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: OTHER): 1 drug or a combination of drugs considered standard anticancer treatment is given according to the result of the sensitivity analysis.

Based on this trial design, predict the completion outcome and termination type (if applicable).